Gastric Acid Clinical Trial
Official title:
Comparison of the Gastric Acid Suppressive Effects of Esomeprazole and Generic Omeprazole
NCT number | NCT00542347 |
Other study ID # | 1054-07 |
Secondary ID | |
Status | Terminated |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | September 2007 |
Est. completion date | July 2018 |
Verified date | July 2018 |
Source | Queen's University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Proton pump inhibitors (PPI) are used to decrease stomach acid secretion. A generic form of omeprazole, one of the PPIs, is on the market. With cheaper than brand name PPIs, it is unclear whether generic omeprazole is as effective clinically. This study compares generic omeprazole with half-dose esomeprazole, the strongest brand name PPI. The half-dose esomeprazole is in fact cheaper than generic omeprazole. Healthy volunteers will take each medication in turn for 7 days and their stomach acid will be measured while taking each medication. We hypothesize that half-dose esomeprazole is better at suppressing stomach acid than generic omeprazole.
Status | Terminated |
Enrollment | 20 |
Est. completion date | July 2018 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - healthy, non-smoking volunteers older than 18 years of age Exclusion Criteria: - history of gastrointestinal disease - known infection - previous eradication of Helicobacter pylori - any prescription or over the counter antacid medication - pregnant and lactating women |
Country | Name | City | State |
---|---|---|---|
Canada | Hotel Dieu Hospital | Kingston | Ontario |
Lead Sponsor | Collaborator |
---|---|
Queen's University | Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median intragastric pH and percentage of time that intragastric pH is above 4 | 24 hours | ||
Secondary | Nocturnal acid breakthrough, defined as at least 60 continuous minutes of intragastric pH below 4 occurring between 10pm and 6 am and adverse events | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00765206 -
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00674115 -
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
|
Phase 3 |